Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

WHO Product Development for Vaccines Product Development Advisory Committee; WHO Product Development for Vaccines Advisory Committee

doi:10.1016/j.vaccine.2016.02.078

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

WHO Product Development for Vaccines Product Development Advisory Committee, WHO Product Development for Vaccines Advisory Committee

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

There are more vaccines in development, against a greater number of pathogens, than ever before. A challenge with this exceptional level of activity and investment is how to select and resource the most promising approaches to have the most significant impact on public health. The WHO Product Development for Vaccines Advisory Committee (PDVAC) was established in 2014 to provide strategic advice and recommendations to WHO for vaccines in clinical development that could have a significant impact on public health in low and middle income countries. On 7-9th September 2015, PDVAC was convened for the second time, when the committee reviewed vaccine developments in 24 disease areas. This report summarises the key recommendations from that consultation.

Original language	English (US)
Pages (from-to)	2865-2869
Number of pages	5
Journal	Vaccine
Volume	34
Issue number	26
DOIs	https://doi.org/10.1016/j.vaccine.2016.02.078
State	Published - Jun 3 2016

Keywords

Candidate
LMIC
PPC
Product development
Vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2016.02.078

Cite this

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. / WHO Product Development for Vaccines Product Development Advisory Committee; WHO Product Development for Vaccines Advisory Committee.
In: Vaccine, Vol. 34, No. 26, 03.06.2016, p. 2865-2869.

Research output: Contribution to journal › Article › peer-review

@article{6b8309e9a6b5484288cf4f4b63b4073e,

title = "Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015",

abstract = "There are more vaccines in development, against a greater number of pathogens, than ever before. A challenge with this exceptional level of activity and investment is how to select and resource the most promising approaches to have the most significant impact on public health. The WHO Product Development for Vaccines Advisory Committee (PDVAC) was established in 2014 to provide strategic advice and recommendations to WHO for vaccines in clinical development that could have a significant impact on public health in low and middle income countries. On 7-9th September 2015, PDVAC was convened for the second time, when the committee reviewed vaccine developments in 24 disease areas. This report summarises the key recommendations from that consultation.",

keywords = "Candidate, LMIC, PPC, Product development, Vaccine",

author = "{WHO Product Development for Vaccines Product Development Advisory Committee} and {WHO Product Development for Vaccines Advisory Committee} and Giersing, {Birgitte K.} and Kayvon Modjarrad and Kaslow, {David C.} and Moorthy, {Vasee S.} and Ashish Bavdekar and Klaus Cichutek and Alejandro Cravioto and Bernard Fritzell and Graham, {Barney S.} and Ruth Karron and Lanata, {Claudio F.} and Mair Powell and Yiming Shao and Peter Smith",

note = "Publisher Copyright: {\textcopyright} 2016 World Health Organization.",

year = "2016",

month = jun,

day = "3",

doi = "10.1016/j.vaccine.2016.02.078",

language = "English (US)",

volume = "34",

pages = "2865--2869",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "26",

}

TY - JOUR

T1 - Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

AU - WHO Product Development for Vaccines Product Development Advisory Committee

AU - WHO Product Development for Vaccines Advisory Committee

AU - Giersing, Birgitte K.

AU - Modjarrad, Kayvon

AU - Kaslow, David C.

AU - Moorthy, Vasee S.

AU - Bavdekar, Ashish

AU - Cichutek, Klaus

AU - Cravioto, Alejandro

AU - Fritzell, Bernard

AU - Graham, Barney S.

AU - Karron, Ruth

AU - Lanata, Claudio F.

AU - Powell, Mair

AU - Shao, Yiming

AU - Smith, Peter

PY - 2016/6/3

Y1 - 2016/6/3

N2 - There are more vaccines in development, against a greater number of pathogens, than ever before. A challenge with this exceptional level of activity and investment is how to select and resource the most promising approaches to have the most significant impact on public health. The WHO Product Development for Vaccines Advisory Committee (PDVAC) was established in 2014 to provide strategic advice and recommendations to WHO for vaccines in clinical development that could have a significant impact on public health in low and middle income countries. On 7-9th September 2015, PDVAC was convened for the second time, when the committee reviewed vaccine developments in 24 disease areas. This report summarises the key recommendations from that consultation.

AB - There are more vaccines in development, against a greater number of pathogens, than ever before. A challenge with this exceptional level of activity and investment is how to select and resource the most promising approaches to have the most significant impact on public health. The WHO Product Development for Vaccines Advisory Committee (PDVAC) was established in 2014 to provide strategic advice and recommendations to WHO for vaccines in clinical development that could have a significant impact on public health in low and middle income countries. On 7-9th September 2015, PDVAC was convened for the second time, when the committee reviewed vaccine developments in 24 disease areas. This report summarises the key recommendations from that consultation.

KW - Candidate

KW - LMIC

KW - PPC

KW - Product development

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84969922928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969922928&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.02.078

DO - 10.1016/j.vaccine.2016.02.078

M3 - Article

C2 - 26993336

AN - SCOPUS:84969922928

SN - 0264-410X

VL - 34

SP - 2865

EP - 2869

JO - Vaccine

JF - Vaccine

IS - 26

ER -

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this